Clinical trial · Interventional
Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients
NCT03007225CI-TRIAL-00047861completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term efficacy and safety in first 3 months after embolization
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HepatoCellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TACE with Drug Eluting Beads procedure | Drug | — | UNRESOLVED |
| Trans-arterial chemoembolization (TACE) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- group 1 Drug eluting beads intervention
- description
- Twenty-five patients underwent Chemoembolization with Drug eluting beads. using Drug eluting Doxorubicin hydrochloride (100-150 mg)
- interventionNames
- Drug: TACE with Drug Eluting Beads procedure
- type
- ACTIVE_COMPARATOR
- label
- group 2 Conventional TACE intervention
- description
- Twenty-five patients underwent conventional Chemoembolization (cTACE) using the standard TACE technique
- interventionNames
- Drug: Trans-arterial chemoembolization (TACE)
Primary outcomes (1)
- measure
- Number of Participants With Complete Response
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of HCC according to the European association of study of liver diseases * Early stage HCC (Stage A), using the Barcelona Clinic Liver Cancer (BCLC) staging system, (single or 3 nodules \< 3cm PS 0) whenever curative measures were contraindicated and BCLC stage B (intermediate HCC). * Patent portal vein and its main branches * Informed consent from all participants before enrollment in the study. Exclusion Criteria: * Patients with Child class C according to Child classification (BCLC D). * Patients with diffuse HCC (non-measurable lesion). * Patients with thrombosis of main portal vein or one of its main branches (BCLC C). * Patients with extra hepatic invasion. * patients refused to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.